Not available
Quote | Voyager Therapeutics Inc. (NASDAQ:VYGR)
Last: | $7.59 |
---|---|
Change Percent: | 0.51% |
Open: | $7.82 |
Close: | $7.59 |
High: | $7.8298 |
Low: | $7.55 |
Volume: | 358,920 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Voyager Therapeutics Inc. (NASDAQ:VYGR)
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
2024-06-13 07:22:19 ET More on Voyager Therapeutics Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis Voyager Therapeutics up 8% following quarterly beats Voyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats...
Message Board Posts | Voyager Therapeutics Inc. (NASDAQ:VYGR)
Subject | By | Source | When |
---|---|---|---|
$VYGR bulls and bears | Argus63 | investorshub | 05/08/2023 7:35:34 PM |
$VYGR The now last trade up | Gary Ray | investorshub | 05/08/2023 12:07:45 PM |
$VYGR bears are running | Gator44 | investorshub | 05/08/2023 9:46:10 AM |
MomentumIts now | Gary Ray | investorshub | 05/08/2023 4:34:43 AM |
$VYGR The trading last up | Argus63 | investorshub | 05/08/2023 1:48:09 AM |
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...